Chemical and biological profile of the fractionated extract of the species Campylopus savannarum (Müll. Hal.) Mitt

The indiscriminate use of allopathic drugs has selected resistant bacterial and fungal populations which represents a severe public health problem worldwide. On the other hand, plants are in a prominent position due to the capability to synthesize structurally complex bioactive metabolites that can be an alternative to resistant microorganisms' control. In this work, we evaluated the chemical composition and the antimicrobial, antioxidant, and cytotoxic potential of the fractionated extract of C. savannarum in ethyl acetate. The extract of C. savannarum was divided into 12 fractions that were submitted to phytochemical screening, minimum inhibitory concentration (MIC), reduction of 1,1-diphenyl-2-picrylhydrazine (DPPH), and hemolytic activity of sheep erythrocytes assays. During the investigation, all extract fractions presented alkaloids, triterpenoids, steroids, and phenolic compounds in qualitative analyses, while in the quantitative evaluation, we observed the presence of both phenols and flavonoids in these fractions. Among the fraction, the highest phenolic content was observed in the Cs23-24 fraction (2.480 mg EAG/g), while the Cs31-34 fractions presented the highest amount of flavonoid (182.25 μg EQ/100 mg). Nine of the 12 fractions of the moss species' extract showed antimicrobial action Against Gram-positive bacteria: Bacillus cereus, Staphylococcus aureus, Micrococcus luteus, Bacillus subtilis; Gram-negative bacteria: Pseudomonas aeruginosa; and also antifungal activity against Candida albicans and Candida glabata. The cytotoxic assay demonstrated that the tested fractions did not induce hemolysis at concentrations 10 and 100(µG/ML). In the antioxidant evaluation, the Cs55-69 fractions were the ones that presented the highest scavenging activity (57, 0%) followed by the Cs45-54 fraction (42.7%). Overall, the evaluation of the biological potential of the fractionated extracts of Campylopus savannarum showed promising data, in the search for natural antimicrobial compounds.

IgE antibodies to hepatitis C virus core and nonstructural antigens in chronic hepatitis C patients before and after antiviral treatment

Few studies on the immunoglobulin E (IgE) immune response in chronic hepatitis C have been reported. In this study, we tested the antigenicity of commercial recombinant hepatitis C virus (HCV) core and nonstructural protein NS3, NS4, and NS5 antigens and the IgE immune response to these antigens in chronic hepatitis C patients before and after antiviral treatment with pegylated interferon (IFN)-α plus ribavirin for 12 weeks. The effects of antiviral treatment were investigated in 20 out of 35 participants. We developed amplified immunoassays using these antigens and IgG-depleted patient sera. Seropositivity for IgE antibodies was determined, and serum IgE and cytokine levels were measured. Anti-core, anti-NS3, and anti-NS4 IgE antibodies were observed in most patients, whereas anti-NS5 antibodies were less prevalent. Antiviral treatment decreased the production of anti-core, anti-NS3, and anti-NS4 IgE antibodies, but not anti-NS5 IgE antibodies. A significant decrease in the anti-NS3 and anti-NS4 IgE antibody levels was observed in patients who presented with an early sustained virological response, but no effects on anti-core and anti-NS5 IgE antibodies was observed. The serum levels of IFN-γ, interleukin (IL)-2, IL-6, tumor necrosis factor-α, and IL-10, but not IL-4, were similar between patients before and after antiviral therapy. Thus, the immune response of IgE antibodies to HCV antigens was comparable to that of anti-HCV IgG antibodies. The usefulness of anti-NS3 IgE antibodies in diagnosing occult hepatitis C and monitoring antiviral treatment with directly acting antiviral medication must be investigated in future studies.

Serum levels of immunoglobulin free light chains in patients with chronic hepatitis C presenting cryoglobulinemia

Hepatitis C virus (HCV) infects B-lymphocytes, provokes cellular dysfunction and causes lymphoproliferative diseases such as cryoglobulinemia and non-Hodgkin's B-cell lymphoma. In the present study, we investigated the serum levels of kappa and lambda free light chains (FLC) of immunoglobulins and the kappa/lambda FLC ratio in Brazilian patients with chronic HCV infection and cryoglobulinemia. We also analyzed the immunochemical composition of the cryoglobulins in these patients. Twenty-eight cryoglobulinemic HCV patients composed the target group, while 37 HCV patients without cryoglobulinemia were included as controls. The median levels of kappa and lambda FLC were higher in patients with cryoglobulinemia compared to controls (p = 0.001 and p = 0.003, respectively), but the kappa/lambda FLC ratio was similar in patients with and without cryoglobulinemia (p > 0.05). The median FLC ratio was higher in HCV patients presenting with advanced fibrosis of the liver compared to HCV patients without fibrosis (p = 0.004). Kappa and lambda FLC levels were strongly correlated with the IgA, IgG and IgM levels in the patients with cryoglobulinemia. In patients without cryoglobulinemia, the kappa FLC level was only correlated with the IgG level, whereas the lambda FLC were weakly correlated with the IgA, IgG and IgM levels. An immunochemical pattern of mixed cryoglobulins (MC), predominantly IgM, IgG, IgA and kappa light chain, was verified in these immune complexes. We concluded that HCV-infected patients presenting cryoglobulinemia have vigorous polyclonal B-lymphocyte activation due to chronic HCV infection and persistent immune stimulation.